Loading...
XSTO
ABLI
Market cap74mUSD
Mar 17, Last price  
0.44SEK
Name

Abliva AB

Chart & Performance

D1W1MN
P/E
—
P/S
5,223.90
EPS
—
Div Yield, %
—
Shrs. gr., 5y
67.36%
Rev. gr., 5y
93.89%
Revenues
137k
+341.94%
0908,6604,432,6733,452,7675,556,0001,113,0005,335,0007,152,0002,502,00014,00027,0005,000134,000216,000151,00031,000137,000
Net income
-96m
L+12.41%
-1,227,131-1,557,575-1,528,500-4,773,642-9,386,000-14,873,000-22,331,000-42,549,000-90,119,000-70,240,000-66,728,000-68,373,000-76,874,000-59,883,000-123,498,000-84,964,000-95,509,000
CFO
-103m
L+1,218.12%
-997,923-2,224,735-637,780-5,011,602-8,588,000-12,222,000-19,090,000-43,632,000-67,220,000-57,377,000-58,124,000-63,829,000-72,412,000-67,558,000-114,075,000-159,560,000-7,802,000-102,840,000
Earnings
Aug 20, 2025

Profile

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
URL
https://abliva.com/
IPO date
Oct 03, 2008
Employees
8
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
137
341.94%
31
-79.47%
Cost of revenue
122,457
143,820
Unusual Expense (Income)
NOPBT
(122,320)
(143,789)
NOPBT Margin
Operating Taxes
(9)
(300)
Tax Rate
NOPAT
(122,311)
(143,489)
Net income
(95,509)
12.41%
(84,964)
-31.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
79,420
752
180,364
BB yield
Debt
Debt current
Long-term debt
848
1,403
Deferred revenue
Other long-term liabilities
1,000
Net debt
(32,670)
(69,917)
(78,090)
Cash flow
Cash from operating activities
(102,840)
(7,802)
(159,560)
CAPEX
(1,187)
(1,290)
(905)
Cash from investing activities
(1,187)
(1,290)
(905)
Cash from financing activities
78,932
414
204,417
FCF
(4,016)
(57,767)
(208,754)
Balance
Cash
32,670
57,664
66,392
Long term investments
13,101
13,101
Excess cash
32,670
70,758
79,491
Stockholders' equity
(896,812)
(835,254)
(740,934)
Invested Capital
958,500
906,396
905,756
ROIC
ROCE
EV
Common stock shares outstanding
1,056,299
739,487
Price
Market cap
EV
EBITDA
1,919
(120,486)
(141,179)
EV/EBITDA
Interest
76
2,764
Interest/NOPBT